Aflibercept vs Ranibizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
Aflibercept · Eylea
Marketed by Regeneron Pharmaceuticals and partners
NCT00509795 · Phase 3 · completed
The trial randomly assigned 1,217 participants and used quadruple blinding with ranibizumab as an active comparator. Its hard clinical primary endpoint—maintaining vision at week 52—met the prespecified non-inferiority criterion for all three aflibercept regimens, supporting a strong evidence grade.
Next expected readout: June 2027 · NCT04932980 (registry estimate)
Reported efficacy
Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 95.1 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 95.9 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 95.1 percentage of patients (spread 0) vs Ranibizumab 0.5mg Q4 94.4 percentage of patients (spread 0) (met)
Result source: NCT00509795
Ranibizumab · Lucentis
Marketed by Roche and partners
NCT00056836 · Phase 3 · completed
The study was randomized and double-masked and enrolled 720 participants, but the registry does not identify the comparator arm or provide results. Because the primary clinical endpoint and whether it was met cannot be verified, the evidence remains limited despite the substantial trial size and controlled design.
Reported efficacy
Losing fewer than 15 letters at 12 months: 94.5% (0.3 mg) and 94.6% (0.5 mg) vs 62.2% sham.
Result source: NCT00056836
Results for Age-Related Macular Degeneration
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Aflibercept: 20 of 20 rows · Ranibizumab: 20 of 20 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Aflibercept Rows use multiple source trials | Ranibizumab Rows use multiple source trials |
|---|---|---|
| BCVA (20/40 responder rate · % of participants | 41% (n=39) vs 56.1% (n=41) Lucentis or Avastin or Eylea @ 17.1wk4.0 mg iSONEPa,b NCT01414153 · Phase 2 · registry result, not featured evidence · combination show 2 more doses47.5% (n=40) vs 56.1% (n=41) Lucentis or Avastin or Eylea @ 17.1wk0.5 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination 26.3% (n=38) vs 56.1% (n=41) Lucentis or Avastin or Eylea @ 17.1wk NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy | 41% (n=39) vs 56.1% (n=41) Lucentis or Avastin or Eylea @ 17.1wk4.0 mg iSONEPa,b NCT01414153 · Phase 2 · registry result, not featured evidence · combination show 2 more doses47.5% (n=40) vs 56.1% (n=41) Lucentis or Avastin or Eylea @ 17.1wk0.5 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination 26.3% (n=38) vs 56.1% (n=41) Lucentis or Avastin or Eylea @ 17.1wk NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy |
| BCVA 20/40 absolute value · percentage points No placebo or comparator arm | 52.5% (n=40) @ 52wkc,d,e NCT01950741 · Phase 4 · registry result, not featured evidence | 46.2% (n=275) @ 52wk0.5 mg as-needed (PRN)a,c,d,e NCT00891735 · Phase 3 · registry result, not featured evidence show 3 more doses52.4% (n=275) @ 52wk0.5 mg monthly NCT00891735 · Phase 3 · registry result, not featured evidence 43.6% (n=273) @ 52wk2.0 mg as-needed (PRN) NCT00891735 · Phase 3 · registry result, not featured evidence 50% (n=274) @ 52wk2.0 mg monthly NCT00891735 · Phase 3 · registry result, not featured evidence |
| BCVA Change Letters absolute change · letters | 3.63 vs 4.34 Lucentis or Avastin or Eylea letters @ 17.1wk4.0 mg iSONEPa,b NCT01414153 · Phase 2 · registry result, not featured evidence · combination show 2 more doses4.22 vs 4.34 Lucentis or Avastin or Eylea letters @ 17.1wk0.5 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination -3.17 vs 4.34 Lucentis or Avastin or Eylea letters @ 17.1wk NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy | 3.63 vs 4.34 Lucentis or Avastin or Eylea letters @ 17.1wk4.0 mg iSONEPa,b NCT01414153 · Phase 2 · registry result, not featured evidence · combination show 2 more doses4.22 vs 4.34 Lucentis or Avastin or Eylea letters @ 17.1wk0.5 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination -3.17 vs 4.34 Lucentis or Avastin or Eylea letters @ 17.1wk NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy |
| BCVA Change Letters absolute change · Letters correctly read No placebo or comparator arm | 10.8 Letters correctly read @ 52wka,c,d,e NCT02120950 · Phase 4 · registry result, not featured evidence · combination show 1 more dose10.7 Letters correctly read @ 52wk NCT02120950 · Phase 4 · registry result, not featured evidence · combination | 1 Letters correctly read @ 52wk0.5 mga,c,d,e NCT01780935 · Phase 3 · registry result, not featured evidence show 1 more dose0.1 Letters correctly read @ 52wk0.5 mg NCT01780935 · Phase 3 · registry result, not featured evidence |
| BCVA Change Letters absolute change · letters No placebo or comparator arm | 9 letters @ 52wka,b,e NCT02305238 · Phase 4 · registry result, not featured evidence show 1 more dose8.4 letters @ 52wk NCT02305238 · Phase 4 · registry result, not featured evidence | 12.3 letters @ 52wk0.5 mg monthlya,b,e NCT01775124 · Phase 4 · registry result, not featured evidence show 1 more dose9.6 letters @ 52wk0.5 mg PRN NCT01775124 · Phase 4 · registry result, not featured evidence |
| BCVA Change Letters absolute change · Letters No placebo or comparator arm | 10.8 Letters @ 52wka,b NCT02120950 · Phase 4 · registry result, not featured evidence · combination show 1 more dose10.7 Letters @ 52wk NCT02120950 · Phase 4 · registry result, not featured evidence · combination | 5.1 Letters @ 52wk0.5 mga,b NCT01846273 · Phase 4 · registry result, not featured evidence show 1 more dose8.3 Letters @ 52wk0.5 mg + vPDT NCT01846273 · Phase 4 · registry result, not featured evidence · combination |
| BCVA Gain 15 Letters absolute value · percentage points | 37.5% (n=304) vs 30.9% (n=304) Ranibizumab @ 52wk2.0mg Q4a,f,b,e,g NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 2 more doses30.6% (n=301) vs 30.9% (n=304) Ranibizumab @ 52wk2.0mg Q8 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 24.9% (n=301) vs 30.9% (n=304) Ranibizumab @ 52wk0.5mg Q4 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 | 39.1% (n=151) vs 34% (n=147) Lucentis @ 24wk1.5 mg / 0.5 mga,f,b,e,g NCT01089517 · Phase 2 · registry result, not featured evidence · combination show 1 more dose33.3% (n=147) vs 34% (n=147) Lucentis @ 24wk0.3 mg / 0.5 mg NCT01089517 · Phase 2 · registry result, not featured evidence · combination |
| BCVA Loss Less Than 15 Letters responder rate · % of participants | 98.7% (n=228) vs 92.1% (n=76) PDT @ 28wkb,e,h NCT01482910 · Phase 3 · registry result, not featured evidence | 94.6% vs 62.2% sham @ 51.96wkRanibizumab 0.5 mga,b,e,h NCT00056836 · Phase 3 · sponsor-reported, not registry data show 1 more dose94.5% vs 62.2% sham @ 51.96wkRanibizumab 0.3 mg NCT00056836 · Phase 3 · sponsor-reported, not registry data |
| CNV Area Change Mm2 absolute change · mm | -4.71 vs -5.3 Lucentis or Avastin or Eylea mm @ 17.1wk4.0 mg iSONEPa,b NCT01414153 · Phase 2 · registry result, not featured evidence · combination show 2 more doses-4.91 vs -5.3 Lucentis or Avastin or Eylea mm @ 17.1wk0.5 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination 0.02 vs -5.3 Lucentis or Avastin or Eylea mm @ 17.1wk NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy | -4.71 vs -5.3 Lucentis or Avastin or Eylea mm @ 17.1wk4.0 mg iSONEPa,b NCT01414153 · Phase 2 · registry result, not featured evidence · combination show 2 more doses-4.91 vs -5.3 Lucentis or Avastin or Eylea mm @ 17.1wk0.5 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination 0.02 vs -5.3 Lucentis or Avastin or Eylea mm @ 17.1wk NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy |
| Complete Polyp Regression event count · % of participants No placebo or comparator arm | 38.5% (n=13) @ 52wk*a,b NCT03117634 · Phase 4 · registry result, not featured evidence · converted to % from 5 Participants as posted show 1 more dose53.8% (n=39) @ 52wk* NCT03117634 · Phase 4 · registry result, not featured evidence · converted to % from 21 Participants as posted | 33.8% (n=154) @ 52wk*0.5 mga,b NCT01846273 · Phase 4 · registry result, not featured evidence · converted to % from 52 Participants as posted show 1 more dose68.5% (n=168) @ 52wk*0.5 mg + vPDT NCT01846273 · Phase 4 · registry result, not featured evidence · combination · converted to % from 115 Participants as posted |
| CRT Change Microns absolute change · m No placebo or comparator arm | -134.4 m @ 52wka,b,e NCT02305238 · Phase 4 · registry result, not featured evidence show 1 more dose-126.1 m @ 52wk NCT02305238 · Phase 4 · registry result, not featured evidence | -147.1 m @ 52wka,b,e NCT01972789 · Phase 4 · registry result, not featured evidence show 1 more dose-125.6 m @ 52wk NCT01972789 · Phase 4 · registry result, not featured evidence |
| CST Change Microns absolute change · m | -46.9 vs -67.7 Lucentis or Avastin or Eylea m @ 17.1wk4.0 mg iSONEPa,b NCT01414153 · Phase 2 · registry result, not featured evidence · combination show 2 more doses-72.4 vs -67.7 Lucentis or Avastin or Eylea m @ 17.1wk0.5 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination 12.9 vs -67.7 Lucentis or Avastin or Eylea m @ 17.1wk NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy | -46.9 vs -67.7 Lucentis or Avastin or Eylea m @ 17.1wk4.0 mg iSONEPa,b NCT01414153 · Phase 2 · registry result, not featured evidence · combination show 2 more doses-72.4 vs -67.7 Lucentis or Avastin or Eylea m @ 17.1wk0.5 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination 12.9 vs -67.7 Lucentis or Avastin or Eylea m @ 17.1wk NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy |
| Lesion Area Change Mm2 absolute change · mm | -4.7 vs -3 REGN910-3 mm @ 36wk2 mg Q4 to 2 mg Q12a,i,b,e,j NCT02713204 · Phase 2 · registry result, not featured evidence show 2 more doses-3.9 vs -3 REGN910-3 mm @ 36wk2 mg Q4 to 2 mg Q8 NCT02713204 · Phase 2 · registry result, not featured evidence -5.3 vs -3 REGN910-3 mm @ 36wk2 mg Q4 to 6 mg:2 mg Q8 NCT02713204 · Phase 2 · registry result, not featured evidence | -0.6382 vs -1.1814 Lucentis mm @ 48wki,b,e,j NCT02611778 · Phase 3 · registry result, not featured evidence |
| NEI VFQ-25 Total absolute change · score | 6.7 vs 4.9 Ranibizumab score @ 52wk2.0mg Q4a,b,e,k NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 2 more doses5.1 vs 4.9 Ranibizumab score @ 52wk2.0mg Q8 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 4.5 vs 4.9 Ranibizumab score @ 52wk0.5mg Q4 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 | 5.3 vs 3.75 Lucentis score @ 48wkb,e,k NCT02611778 · Phase 3 · registry result, not featured evidence |
| NEI VFQ-25 Total absolute change · score No placebo or comparator arm | 7.3 score @ 52wka,c,b,e NCT02120950 · Phase 4 · registry result, not featured evidence · combination show 1 more dose4.7 score @ 52wk NCT02120950 · Phase 4 · registry result, not featured evidence · combination | 2.3 score @ 52wk0.5 mg treat-and-extenda,c,b,e NCT01948830 · Phase 3 · registry result, not featured evidence show 1 more dose4 score @ 52wk0.5 mg monthly NCT01948830 · Phase 3 · registry result, not featured evidence |
| no IRF and no SRF Center Subfield event count · % of participants No placebo or comparator arm | 50.9% (n=53) @ 16wk*l,b,e,m NCT04126317 · Phase 2 · registry result, not featured evidence · converted to % from 27 Participants as posted | 37.2% (n=172) @ 104wk*a,l,b,e,m NCT01972789 · Phase 4 · registry result, not featured evidence · converted to % from 64 Participants as posted show 1 more dose32.4% (n=173) @ 104wk* NCT01972789 · Phase 4 · registry result, not featured evidence · converted to % from 56 Participants as posted |
| Dropout rate | 3.6%2.0mg Q4n NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 44 more results8.9%2.0mg Q8 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 8.9%0.5mg Q4 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 10.2%2 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 9.3%2 mg Q8 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 11.9%0.5 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 0%Fixed Group NCT03117634 · Phase 4 · registry result, not featured evidence 4.9%Personalised Group NCT03117634 · Phase 4 · registry result, not featured evidence 7.7% NCT03022292 · Phase 4 · registry result, not featured evidence 6.1% NCT02689518 · Phase 4 · registry result, not featured evidence 11.9%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 14%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 12.9%2 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 15.4%4 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 100%Aflibercept (Non-randomized) NCT02120950 · Phase 4 · registry result, not featured evidence 8.7%Aflibercept + Active PDT NCT02120950 · Phase 4 · registry result, not featured evidence · combination —Aflibercept + Sham PDT NCT02120950 · Phase 4 · registry result, not featured evidence · combination 12.7%Aflibercept + Sham Photodynamic Th NCT02120950 · Phase 4 · registry result, not featured evidence · combination 18.2% NCT01722045 · Phase 4 · registry result, not featured evidence 6.3% NCT01950741 · Phase 4 · registry result, not featured evidence 2.2%2.0 mg NCT01543568 · Phase 4 · registry result, not featured evidence 0%8 mg NCT05989126 · Phase 3 · registry result, not featured evidence 8.3%2 mg every 8 weeks NCT02540954 · Phase 3 · registry result, not featured evidence 11.3%Aflibercept Extended Dosing NCT02540954 · Phase 3 · registry result, not featured evidence —6 mg NCT03386474 · Phase 3 · registry result, not featured evidence 0.9%Brolucizumab - Overall Extension S NCT03386474 · Phase 3 · registry result, not featured evidence —Brolucizumab Overall Last 6 Months NCT03386474 · Phase 3 · registry result, not featured evidence 6.6%Aflibercept Injection (EYLEA, VEGF NCT01482910 · Phase 3 · registry result, not featured evidence —Aflibercept Injection, From Week 2 NCT01482910 · Phase 3 · registry result, not featured evidence —Aflibercept Injection, up to Week NCT01482910 · Phase 3 · registry result, not featured evidence —PDT Then Aflibercept Injection, Fr NCT01482910 · Phase 3 · registry result, not featured evidence · combination 95% NCT00964795 · Phase 3 · registry result, not featured evidence 9.7%RBM-007 + Aflibercept NCT04200248 · Phase 2 · registry result, not featured evidence · combination 9.4%Sham + RBM-007 NCT04200248 · Phase 2 · registry result, not featured evidence · combination 3.8% NCT04126317 · Phase 2 · registry result, not featured evidence 10.3%4.0 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination 5%0.5 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination 21.1%Monotherapy NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy 23.6%2mg NCT00527423 · Phase 2 · registry result, not featured evidence —2.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —2.0 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —4.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence 22.5% NCT01773954 · Phase na · registry result, not featured evidence | 10.7%o NCT02161575 · Phase 4 · registry result, not featured evidence show 51 more results23%0.5 mg NCT01846273 · Phase 4 · registry result, not featured evidence 13.1%0.5 mg + vPDT NCT01846273 · Phase 4 · registry result, not featured evidence · combination 0%0.5 mg + vPDT NCT01846273 · Phase 4 · registry result, not featured evidence · combination —Intensive NCT01972789 · Phase 4 · registry result, not featured evidence 23%Intensive Retinal Fluid Regimen NCT01972789 · Phase 4 · registry result, not featured evidence —Relaxed NCT01972789 · Phase 4 · registry result, not featured evidence 17.1%Relaxed Retinal Fluid Regimen NCT01972789 · Phase 4 · registry result, not featured evidence —0.5 mg NCT02140411 · Phase 4 · registry result, not featured evidence 4.8%Ranibizumab NCT02140411 · Phase 4 · registry result, not featured evidence —0.5 mg NCT01986907 · Phase 4 · registry result, not featured evidence 17.3%Ranibizumab NCT01986907 · Phase 4 · registry result, not featured evidence 6.5%0.5 mg monthly NCT01775124 · Phase 4 · registry result, not featured evidence 6%0.5 mg PRN NCT01775124 · Phase 4 · registry result, not featured evidence 20.4% NCT01810042 · Phase 4 · registry result, not featured evidence — NCT01464723 · Phase 4 · registry result, not featured evidence 9.1%50% Fluence PDT NCT00473642 · Phase 4 · registry result, not featured evidence · combination 20%Ranibizumab NCT00473642 · Phase 4 · registry result, not featured evidence 20%Standard Fluence PDT NCT00473642 · Phase 4 · registry result, not featured evidence · combination 5% NCT02611778 · Phase 3 · registry result, not featured evidence 10%0.5 mg monthly NCT01748292 · Phase 3 · registry result, not featured evidence 30%0.5 mg treat-and-extend NCT01748292 · Phase 3 · registry result, not featured evidence — NCT02698566 · Phase 3 · registry result, not featured evidence 10.2%0.5 mg treat-and-extend NCT01948830 · Phase 3 · registry result, not featured evidence 9.8%0.5 mg monthly NCT01948830 · Phase 3 · registry result, not featured evidence n/a: no completion milestone0.5 mg NCT01780935 · Phase 3 · registry result, not featured evidence n/a: no completion milestone0.5 mg NCT01780935 · Phase 3 · registry result, not featured evidence 4.4%0.5 mg as-needed (PRN) NCT00891735 · Phase 3 · registry result, not featured evidence 6.2%0.5 mg monthly NCT00891735 · Phase 3 · registry result, not featured evidence 5.5%2.0 mg as-needed (PRN) NCT00891735 · Phase 3 · registry result, not featured evidence 5.8%2.0 mg monthly NCT00891735 · Phase 3 · registry result, not featured evidence 22.2%Ranibizumab ANCHOR NCT00331864 · Phase 3 · registry result, not featured evidence 11.3%Ranibizumab Non-ANCHOR NCT00331864 · Phase 3 · registry result, not featured evidence 19.5%0.5 mg - 3 Times Monthly, Then Quarterly NCT00275821 · Phase 3 · registry result, not featured evidence 11.7%0.3 mg - 3 Times Monthly, Then Quarterly NCT00275821 · Phase 3 · registry result, not featured evidence 10.4%0.3 mg Monthly NCT00275821 · Phase 3 · registry result, not featured evidence 8.3%0.5 mg monthly NCT00764738 · Phase 2/3 · registry result, not featured evidence 10.7%0.5 mg PRN NCT00764738 · Phase 2/3 · registry result, not featured evidence 20%2.0 mg monthly NCT00764738 · Phase 2/3 · registry result, not featured evidence 25%2.0 mg PRN NCT00764738 · Phase 2/3 · registry result, not featured evidence 10.7%4.0 mg NCT03211234 · Phase 2 · registry result, not featured evidence · combination 3.2%2.0 mg NCT03211234 · Phase 2 · registry result, not featured evidence · combination 12.5% NCT01914159 · Phase 2 · registry result, not featured evidence 10.3%4.0 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination 5%0.5 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination 21.1%Monotherapy NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy 0%Ranibizumab Group 1 NCT00896779 · Phase 2 · registry result, not featured evidence 8.3%Ranibizumab Group 2 NCT00896779 · Phase 2 · registry result, not featured evidence 3.3%1.5 mg / 0.5 mg NCT01089517 · Phase 2 · registry result, not featured evidence · combination 3.4%0.3 mg / 0.5 mg NCT01089517 · Phase 2 · registry result, not featured evidence · combination —high dose NCT01089517 · Phase 2 · registry result, not featured evidence · combination —low dose NCT01089517 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 1%2.0mg Q4n NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 44 more results1.3%2.0mg Q8 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 1.6%0.5mg Q4 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 1.9%2 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 2.9%2 mg Q8 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 2.6%0.5 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 —Fixed Group NCT03117634 · Phase 4 · registry result, not featured evidence —Personalised Group NCT03117634 · Phase 4 · registry result, not featured evidence — NCT03022292 · Phase 4 · registry result, not featured evidence — NCT02689518 · Phase 4 · registry result, not featured evidence 3%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 4.4%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 3.2%2 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 1.6%4 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 20%Aflibercept (Non-randomized) NCT02120950 · Phase 4 · registry result, not featured evidence 2.5%Aflibercept + Active PDT NCT02120950 · Phase 4 · registry result, not featured evidence · combination —Aflibercept + Sham PDT NCT02120950 · Phase 4 · registry result, not featured evidence · combination 3.2%Aflibercept + Sham Photodynamic Th NCT02120950 · Phase 4 · registry result, not featured evidence · combination 5.2% NCT01722045 · Phase 4 · registry result, not featured evidence — NCT01950741 · Phase 4 · registry result, not featured evidence —2.0 mg NCT01543568 · Phase 4 · registry result, not featured evidence —8 mg NCT05989126 · Phase 3 · registry result, not featured evidence 1.2%2 mg every 8 weeks NCT02540954 · Phase 3 · registry result, not featured evidence 2.4%Aflibercept Extended Dosing NCT02540954 · Phase 3 · registry result, not featured evidence —6 mg NCT03386474 · Phase 3 · registry result, not featured evidence 0%Brolucizumab - Overall Extension S NCT03386474 · Phase 3 · registry result, not featured evidence —Brolucizumab Overall Last 6 Months NCT03386474 · Phase 3 · registry result, not featured evidence 2.6%Aflibercept Injection (EYLEA, VEGF NCT01482910 · Phase 3 · registry result, not featured evidence —Aflibercept Injection, From Week 2 NCT01482910 · Phase 3 · registry result, not featured evidence —Aflibercept Injection, up to Week NCT01482910 · Phase 3 · registry result, not featured evidence —PDT Then Aflibercept Injection, Fr NCT01482910 · Phase 3 · registry result, not featured evidence · combination 3.7% NCT00964795 · Phase 3 · registry result, not featured evidence —RBM-007 + Aflibercept NCT04200248 · Phase 2 · registry result, not featured evidence · combination —Sham + RBM-007 NCT04200248 · Phase 2 · registry result, not featured evidence · combination 1.9% NCT04126317 · Phase 2 · registry result, not featured evidence —4.0 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination —0.5 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination —Monotherapy NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy 3.2%2mg NCT00527423 · Phase 2 · registry result, not featured evidence —2.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —2.0 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —4.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence — NCT01773954 · Phase na · registry result, not featured evidence | 1.9%o NCT02161575 · Phase 4 · registry result, not featured evidence show 51 more results6.2%0.5 mg NCT01846273 · Phase 4 · registry result, not featured evidence 5.4%0.5 mg + vPDT NCT01846273 · Phase 4 · registry result, not featured evidence · combination 0%0.5 mg + vPDT NCT01846273 · Phase 4 · registry result, not featured evidence · combination —Intensive NCT01972789 · Phase 4 · registry result, not featured evidence 6.3%Intensive Retinal Fluid Regimen NCT01972789 · Phase 4 · registry result, not featured evidence —Relaxed NCT01972789 · Phase 4 · registry result, not featured evidence 2.3%Relaxed Retinal Fluid Regimen NCT01972789 · Phase 4 · registry result, not featured evidence —0.5 mg NCT02140411 · Phase 4 · registry result, not featured evidence 4.8%Ranibizumab NCT02140411 · Phase 4 · registry result, not featured evidence —0.5 mg NCT01986907 · Phase 4 · registry result, not featured evidence 1.2%Ranibizumab NCT01986907 · Phase 4 · registry result, not featured evidence 3%0.5 mg monthly NCT01775124 · Phase 4 · registry result, not featured evidence 3%0.5 mg PRN NCT01775124 · Phase 4 · registry result, not featured evidence — NCT01810042 · Phase 4 · registry result, not featured evidence — NCT01464723 · Phase 4 · registry result, not featured evidence —50% Fluence PDT NCT00473642 · Phase 4 · registry result, not featured evidence · combination —Ranibizumab NCT00473642 · Phase 4 · registry result, not featured evidence —Standard Fluence PDT NCT00473642 · Phase 4 · registry result, not featured evidence · combination 0.4% NCT02611778 · Phase 3 · registry result, not featured evidence 10%0.5 mg monthly NCT01748292 · Phase 3 · registry result, not featured evidence 10%0.5 mg treat-and-extend NCT01748292 · Phase 3 · registry result, not featured evidence — NCT02698566 · Phase 3 · registry result, not featured evidence 2.8%0.5 mg treat-and-extend NCT01948830 · Phase 3 · registry result, not featured evidence 0.6%0.5 mg monthly NCT01948830 · Phase 3 · registry result, not featured evidence 0.6%0.5 mg NCT01780935 · Phase 3 · registry result, not featured evidence 1.2%0.5 mg NCT01780935 · Phase 3 · registry result, not featured evidence 0.7%0.5 mg as-needed (PRN) NCT00891735 · Phase 3 · registry result, not featured evidence 0.7%0.5 mg monthly NCT00891735 · Phase 3 · registry result, not featured evidence 0%2.0 mg as-needed (PRN) NCT00891735 · Phase 3 · registry result, not featured evidence 0%2.0 mg monthly NCT00891735 · Phase 3 · registry result, not featured evidence 5.6%Ranibizumab ANCHOR NCT00331864 · Phase 3 · registry result, not featured evidence 5.8%Ranibizumab Non-ANCHOR NCT00331864 · Phase 3 · registry result, not featured evidence 10.2%0.5 mg - 3 Times Monthly, Then Quarterly NCT00275821 · Phase 3 · registry result, not featured evidence 3.3%0.3 mg - 3 Times Monthly, Then Quarterly NCT00275821 · Phase 3 · registry result, not featured evidence 4.3%0.3 mg Monthly NCT00275821 · Phase 3 · registry result, not featured evidence —0.5 mg monthly NCT00764738 · Phase 2/3 · registry result, not featured evidence —0.5 mg PRN NCT00764738 · Phase 2/3 · registry result, not featured evidence —2.0 mg monthly NCT00764738 · Phase 2/3 · registry result, not featured evidence —2.0 mg PRN NCT00764738 · Phase 2/3 · registry result, not featured evidence —4.0 mg NCT03211234 · Phase 2 · registry result, not featured evidence · combination —2.0 mg NCT03211234 · Phase 2 · registry result, not featured evidence · combination — NCT01914159 · Phase 2 · registry result, not featured evidence —4.0 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination —0.5 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination —Monotherapy NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy —Ranibizumab Group 1 NCT00896779 · Phase 2 · registry result, not featured evidence —Ranibizumab Group 2 NCT00896779 · Phase 2 · registry result, not featured evidence —1.5 mg / 0.5 mg NCT01089517 · Phase 2 · registry result, not featured evidence · combination —0.3 mg / 0.5 mg NCT01089517 · Phase 2 · registry result, not featured evidence · combination —high dose NCT01089517 · Phase 2 · registry result, not featured evidence · combination —low dose NCT01089517 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 23%2.0mg Q4n NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 44 more results29.7%2.0mg Q8 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 28.9%0.5mg Q4 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 26.2%2 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 26.4%2 mg Q8 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 24.2%0.5 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 0%Fixed Group NCT03117634 · Phase 4 · registry result, not featured evidence 7.7%Personalised Group NCT03117634 · Phase 4 · registry result, not featured evidence 3.8% NCT03022292 · Phase 4 · registry result, not featured evidence — NCT02689518 · Phase 4 · registry result, not featured evidence 21.5%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 25.7%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 15.3%2 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 16.3%4 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 26.7%Aflibercept (Non-randomized) NCT02120950 · Phase 4 · registry result, not featured evidence 15.5%Aflibercept + Active PDT NCT02120950 · Phase 4 · registry result, not featured evidence · combination 17.2%Aflibercept + Sham PDT NCT02120950 · Phase 4 · registry result, not featured evidence · combination —Aflibercept + Sham Photodynamic Th NCT02120950 · Phase 4 · registry result, not featured evidence · combination 29.2% NCT01722045 · Phase 4 · registry result, not featured evidence 2.1% NCT01950741 · Phase 4 · registry result, not featured evidence 20%2.0 mg NCT01543568 · Phase 4 · registry result, not featured evidence 5.7%8 mg NCT05989126 · Phase 3 · registry result, not featured evidence 13.7%2 mg every 8 weeks NCT02540954 · Phase 3 · registry result, not featured evidence 15.6%Aflibercept Extended Dosing NCT02540954 · Phase 3 · registry result, not featured evidence 6.5%6 mg NCT03386474 · Phase 3 · registry result, not featured evidence —Brolucizumab - Overall Extension S NCT03386474 · Phase 3 · registry result, not featured evidence 6.5%Brolucizumab Overall Last 6 Months NCT03386474 · Phase 3 · registry result, not featured evidence —Aflibercept Injection (EYLEA, VEGF NCT01482910 · Phase 3 · registry result, not featured evidence 2.3%Aflibercept Injection, From Week 2 NCT01482910 · Phase 3 · registry result, not featured evidence 5.7%Aflibercept Injection, up to Week NCT01482910 · Phase 3 · registry result, not featured evidence 4.2%PDT Then Aflibercept Injection, Fr NCT01482910 · Phase 3 · registry result, not featured evidence · combination 32.5% NCT00964795 · Phase 3 · registry result, not featured evidence 6.9%RBM-007 + Aflibercept NCT04200248 · Phase 2 · registry result, not featured evidence · combination 7.1%Sham + RBM-007 NCT04200248 · Phase 2 · registry result, not featured evidence · combination 13.2% NCT04126317 · Phase 2 · registry result, not featured evidence 10.3%4.0 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination 10%0.5 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination 15.8%Monotherapy NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy 45.9%2mg NCT00527423 · Phase 2 · registry result, not featured evidence —2.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —2.0 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —4.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence 5% NCT01773954 · Phase na · registry result, not featured evidence | 10%o NCT02161575 · Phase 4 · registry result, not featured evidence show 51 more results17%0.5 mg NCT01846273 · Phase 4 · registry result, not featured evidence 15.7%0.5 mg + vPDT NCT01846273 · Phase 4 · registry result, not featured evidence · combination 14.3%0.5 mg + vPDT NCT01846273 · Phase 4 · registry result, not featured evidence · combination 33.5%Intensive NCT01972789 · Phase 4 · registry result, not featured evidence —Intensive Retinal Fluid Regimen NCT01972789 · Phase 4 · registry result, not featured evidence 33.3%Relaxed NCT01972789 · Phase 4 · registry result, not featured evidence —Relaxed Retinal Fluid Regimen NCT01972789 · Phase 4 · registry result, not featured evidence 28.6%0.5 mg NCT02140411 · Phase 4 · registry result, not featured evidence —Ranibizumab NCT02140411 · Phase 4 · registry result, not featured evidence 6.7%0.5 mg NCT01986907 · Phase 4 · registry result, not featured evidence —Ranibizumab NCT01986907 · Phase 4 · registry result, not featured evidence 14.5%0.5 mg monthly NCT01775124 · Phase 4 · registry result, not featured evidence 14.5%0.5 mg PRN NCT01775124 · Phase 4 · registry result, not featured evidence 4.1% NCT01810042 · Phase 4 · registry result, not featured evidence — NCT01464723 · Phase 4 · registry result, not featured evidence 0%50% Fluence PDT NCT00473642 · Phase 4 · registry result, not featured evidence · combination 20%Ranibizumab NCT00473642 · Phase 4 · registry result, not featured evidence 0%Standard Fluence PDT NCT00473642 · Phase 4 · registry result, not featured evidence · combination 8% NCT02611778 · Phase 3 · registry result, not featured evidence 35%0.5 mg monthly NCT01748292 · Phase 3 · registry result, not featured evidence 57.5%0.5 mg treat-and-extend NCT01748292 · Phase 3 · registry result, not featured evidence 0% NCT02698566 · Phase 3 · registry result, not featured evidence 12.1%0.5 mg treat-and-extend NCT01948830 · Phase 3 · registry result, not featured evidence 12.9%0.5 mg monthly NCT01948830 · Phase 3 · registry result, not featured evidence 9%0.5 mg NCT01780935 · Phase 3 · registry result, not featured evidence 13.4%0.5 mg NCT01780935 · Phase 3 · registry result, not featured evidence 20.7%0.5 mg as-needed (PRN) NCT00891735 · Phase 3 · registry result, not featured evidence 24.1%0.5 mg monthly NCT00891735 · Phase 3 · registry result, not featured evidence 19.9%2.0 mg as-needed (PRN) NCT00891735 · Phase 3 · registry result, not featured evidence 19.7%2.0 mg monthly NCT00891735 · Phase 3 · registry result, not featured evidence 22.2%Ranibizumab ANCHOR NCT00331864 · Phase 3 · registry result, not featured evidence 15.6%Ranibizumab Non-ANCHOR NCT00331864 · Phase 3 · registry result, not featured evidence 19.5%0.5 mg - 3 Times Monthly, Then Quarterly NCT00275821 · Phase 3 · registry result, not featured evidence 12.5%0.3 mg - 3 Times Monthly, Then Quarterly NCT00275821 · Phase 3 · registry result, not featured evidence 17.4%0.3 mg Monthly NCT00275821 · Phase 3 · registry result, not featured evidence 0%0.5 mg monthly NCT00764738 · Phase 2/3 · registry result, not featured evidence 8%0.5 mg PRN NCT00764738 · Phase 2/3 · registry result, not featured evidence 0%2.0 mg monthly NCT00764738 · Phase 2/3 · registry result, not featured evidence 0%2.0 mg PRN NCT00764738 · Phase 2/3 · registry result, not featured evidence 14.3%4.0 mg NCT03211234 · Phase 2 · registry result, not featured evidence · combination 3.2%2.0 mg NCT03211234 · Phase 2 · registry result, not featured evidence · combination 0% NCT01914159 · Phase 2 · registry result, not featured evidence 10.3%4.0 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination 10%0.5 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination 15.8%Monotherapy NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy 0%Ranibizumab Group 1 NCT00896779 · Phase 2 · registry result, not featured evidence 0%Ranibizumab Group 2 NCT00896779 · Phase 2 · registry result, not featured evidence —1.5 mg / 0.5 mg NCT01089517 · Phase 2 · registry result, not featured evidence · combination —0.3 mg / 0.5 mg NCT01089517 · Phase 2 · registry result, not featured evidence · combination 6.6%high dose NCT01089517 · Phase 2 · registry result, not featured evidence · combination 9.4%low dose NCT01089517 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 2.0mg Q4n vitreous floaters 16.1% nasopharyngitis 15.1% eye disorders pain 12.8% NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 39 more results2.0mg Q8 nasopharyngitis 12.9% hypertension 10.9% eye disorders pain 10.2% NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 0.5mg Q4 nasopharyngitis 13.5% retinal haemorrhage 11.8% eye disorders pain 11.5% NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 2 mg Q4 retinal haemorrhage 27.2% visual acuity reduced 14.2% hypertension 13.3% NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 2 mg Q8 retinal haemorrhage 26.7% visual acuity reduced 19.5% macular degeneration 16.6% NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 0.5 mg Q4 retinal haemorrhage 23.6% visual acuity reduced 18.5% conjunctival haemorrhage 15.5% NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 drop in visual acuity 7.7% punctate epithelial erosion 7.7% raised blood pressure 7.7% NCT03117634 · Phase 4 · registry result, not featured evidence drop in vision due to cataract 5.1% drop in visual acuity 5.1% peri-orbital oedema (extra-ocular) 2.6% NCT03117634 · Phase 4 · registry result, not featured evidence myelodysplastic syndrome 3.8% pneumonia 3.8% NCT03022292 · Phase 4 · registry result, not featured evidence 2 mg intravitreal visual acuity reduced 15.6% conjunctival haemorrhage 14.8% nasopharyngitis 13.3% NCT02581891 · Phase 4 · registry result, not featured evidence 2 mg intravitreal conjunctival haemorrhage 13.2% nasopharyngitis 12.5% visual acuity reduced 12.5% NCT02581891 · Phase 4 · registry result, not featured evidence nasopharyngitis 21% cataract 4% conjunctival haemorrhage 3.2% NCT02305238 · Phase 4 · registry result, not featured evidence nasopharyngitis 16.3% cataract 8.1% conjunctival haemorrhage 6.5% NCT02305238 · Phase 4 · registry result, not featured evidence hypertension 13.3% depression 6.7% ocular hypertension 6.7% NCT02120950 · Phase 4 · registry result, not featured evidence viral upper respiratory tract infection 11.2% hypertension 8.1% dry eye 6.8% NCT02120950 · Phase 4 · registry result, not featured evidence · combination viral upper respiratory tract infection 15.9% conjunctival haemorrhage 6.4% vitreous floaters 5.7% NCT02120950 · Phase 4 · registry result, not featured evidence · combination neovascular age-related macular degeneration 13% hypertension 8.4% conjunctival haemorrhage 7.8% NCT01722045 · Phase 4 · registry result, not featured evidence conjunctival hemorrhage 8.5% NCT01950741 · Phase 4 · registry result, not featured evidence 2.0 mg cataract progression 6.7% geographic atrophy progression 6.7% NCT01543568 · Phase 4 · registry result, not featured evidence 2 mg every 8 weeks cataract 11.3% subretinal fluid 8.3% nasopharyngitis 7.1% NCT02540954 · Phase 3 · registry result, not featured evidence cataract 10.2% subretinal fluid 8.4% visual acuity reduced 8.4% NCT02540954 · Phase 3 · registry result, not featured evidence 6 mg nasopharyngitis 4.7% urinary tract infection 3.7% neovascular age-related macular degeneration - fellow eye 1.9% NCT03386474 · Phase 3 · registry result, not featured evidence urinary tract infection 5.6% nasopharyngitis 3.7% neovascular age-related macular degeneration - fellow eye 1.9% NCT03386474 · Phase 3 · registry result, not featured evidence conjunctival haemorrhage 6% macular fibrosis 2.8% retinal pigment epitheliopathy 2.8% NCT01482910 · Phase 3 · registry result, not featured evidence macular fibrosis 11.8% visual acuity reduced 7% conjunctival haemorrhage 6.1% NCT01482910 · Phase 3 · registry result, not featured evidence visual acuity reduced 7% conjunctival haemorrhage 5.6% intraocular pressure increased 1.4% NCT01482910 · Phase 3 · registry result, not featured evidence · combination retinal haemorrhage 12.1% retinal haemorrhage 10.5% age-related macular degeneration 9.3% NCT00964795 · Phase 3 · registry result, not featured evidence eye disorders 51.7% conjunctival haemorrhage 20.7% eye irritation 6.9% NCT04200248 · Phase 2 · registry result, not featured evidence · combination eye disorders 46.4% conjunctival haemorrhage 17.9% dry eye 14.3% NCT04200248 · Phase 2 · registry result, not featured evidence · combination neovascular age-related macular degeneration fellow eye 7.5% vitreous detachment study eye 7.5% conjunctival haemorrhage fellow eye 5.7% NCT04126317 · Phase 2 · registry result, not featured evidence 4.0 mg iSONEP conjunctival haemorrhage 53.8% intraocular pressure increased 28.2% vitreous floaters 20.5% NCT01414153 · Phase 2 · registry result, not featured evidence · combination 0.5 mg iSONEP conjunctival haemorrhage 60% activated partial thromboplastin time prolonged 12.5% vitreous floaters 12.5% NCT01414153 · Phase 2 · registry result, not featured evidence · combination conjunctival haemorrhage 34.2% retinal haemorrhage 28.9% arthralgia 7.9% NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy 2mg fall 18.5% hypertension 16.6% nasopharyngitis 16.6% NCT00527423 · Phase 2 · registry result, not featured evidence 2.0 mg q12 upper respiratory tract infection 19.4% blepharitis 9.7% retinal haemorrhage 9.7% NCT00320788 · Phase 2 · registry result, not featured evidence 2.0 mg q4 urinary tract infection 19.4% eye pain 12.9% visual acuity reduced 12.9% NCT00320788 · Phase 2 · registry result, not featured evidence 0.5 mg q12 refraction disorder 12.5% headache 9.4% intraocular pressure increased 9.4% NCT00320788 · Phase 2 · registry result, not featured evidence 0.5 mg q4 hypertension 18.8% bronchitis 15.6% constipation 15.6% NCT00320788 · Phase 2 · registry result, not featured evidence 4.0 mg q12 vitreous detachment 12.9% bronchitis 9.7% eye pain 9.7% NCT00320788 · Phase 2 · registry result, not featured evidence | o nasopharyngitis 9% cough 7% lower respiratory tract infection 7% NCT02161575 · Phase 4 · registry result, not featured evidence show 38 more results0.5 mg nasopharyngitis 7.4% dizziness 3.7% hypertension 3.7% NCT01846273 · Phase 4 · registry result, not featured evidence 0.5 mg + vPDT nasopharyngitis 13.4% retinal haemorrhage (study eye) 7% upper respiratory tract infection 7% NCT01846273 · Phase 4 · registry result, not featured evidence · combination 0.5 mg + vPDT intraocular pressure increased (study eye) 28.6% cerumen impaction 14.3% fasciitis 14.3% NCT01846273 · Phase 4 · registry result, not featured evidence · combination eye pain 16.2% influenza 15% influenza(non-ocular) 15% NCT01972789 · Phase 4 · registry result, not featured evidence nasopharyngitis 16.7% nasopharyngitis(non-ocular) 16.7% eye pain 13.8% NCT01972789 · Phase 4 · registry result, not featured evidence 0.5 mg oedema peripheral 19% back pain 9.5% bronchitis 9.5% NCT02140411 · Phase 4 · registry result, not featured evidence 0.5 mg neovascular age-related macular degeneration 3.6% influenza 1.6% conjunctival haemorrhage 1.4% NCT01986907 · Phase 4 · registry result, not featured evidence 0.5 mg monthly nasopharyngitis 14.5% conjunctival haemorrhage 12.7% upper respiratory tract infection 8.4% NCT01775124 · Phase 4 · registry result, not featured evidence 0.5 mg PRN nasopharyngitis 10.8% conjunctival haemorrhage 7.2% intraocular pressure increased 7.2% NCT01775124 · Phase 4 · registry result, not featured evidence neovascular age-related macular degeneration 8% conjunctival haemorrhage 5.9% nasopharyngitis 5% NCT02611778 · Phase 3 · registry result, not featured evidence 0.5 mg monthly hollenhorst plaque 5% subretinal hemorrhage 5% progressive macular atrophy 0% NCT01748292 · Phase 3 · registry result, not featured evidence 0.5 mg treat-and-extend progressive macular atrophy 7.5% subretinal hemorrhage 2.5% hollenhorst plaque 0% NCT01748292 · Phase 3 · registry result, not featured evidence conjunctival hemorrhage 2.9% NCT02698566 · Phase 3 · registry result, not featured evidence 0.5 mg treat-and-extend intraocular pressure increased (study eye) 8.4% hypertension 7.1% nasopharyngitis 5.6% NCT01948830 · Phase 3 · registry result, not featured evidence 0.5 mg monthly intraocular pressure increased (study eye) 8.6% nasopharyngitis 8% conjunctival haemorrhage (study eye) 5.8% NCT01948830 · Phase 3 · registry result, not featured evidence 0.5 mg nasopharyngitis 7.2% conjunctival haemorrhage (study eye) 5.7% hypertension 5.4% NCT01780935 · Phase 3 · registry result, not featured evidence 0.5 mg intraocular pressure increased (study eye) 6.3% hypertension 4.5% influenza 4.5% NCT01780935 · Phase 3 · registry result, not featured evidence 0.5 mg as-needed (PRN) conjunctival haemorrhage 17.5% sinusitis 9.8% hypertension 7.6% NCT00891735 · Phase 3 · registry result, not featured evidence 0.5 mg monthly conjunctival haemorrhage 23% vitreous floaters 9.5% vitreous detachment 8% NCT00891735 · Phase 3 · registry result, not featured evidence 2.0 mg as-needed (PRN) conjunctival haemorrhage 15.1% vitreous detachment 9.9% eye pain 8.5% NCT00891735 · Phase 3 · registry result, not featured evidence 2.0 mg monthly conjunctival haemorrhage 18.6% eye pain 9.1% vitreous detachment 8.8% NCT00891735 · Phase 3 · registry result, not featured evidence retinal haemorrhage (study eye) 27.8% choroidal neovascularisation (fellow eye) 11.1% choroidal neovascularisation (study eye) 11.1% NCT00331864 · Phase 3 · registry result, not featured evidence visual acuity reduced (study eye) 18.3% intraocular pressure increased (study eye) 7% retinal haemorrhage (study eye) 6.8% NCT00331864 · Phase 3 · registry result, not featured evidence 0.5 mg - 3 Times Monthly, Then Quarterly conjunctival haemorrhage (study eye) 16.1% visual acuity reduced (study eye) 16.1% eye pain (study eye) 11.9% NCT00275821 · Phase 3 · registry result, not featured evidence 0.3 mg - 3 Times Monthly, Then Quarterly conjunctival haemorrhage (study eye) 19.2% eye pain (study eye) 18.3% visual acuity reduced (study eye) 12.5% NCT00275821 · Phase 3 · registry result, not featured evidence 0.3 mg Monthly eye pain (study eye) 20.9% intraocular pressure increased (study eye) 14.8% conjunctival haemorrhage (study eye) 10.4% NCT00275821 · Phase 3 · registry result, not featured evidence 0.5 mg monthly injection site irritation 4.5% corneal abrasion 0% NCT00764738 · Phase 2/3 · registry result, not featured evidence 0.5 mg PRN corneal abrasion 4% injection site irritation 4% NCT00764738 · Phase 2/3 · registry result, not featured evidence 4.0 mg conjunctival hyperaemia 14.3% (placebo 0%) eyelid oedema 10.7% (placebo 0%) retinal haemorrhage 10.7% (placebo 0%) NCT03211234 · Phase 2 · registry result, not featured evidence · combination 2.0 mg eye pain 12.9% (placebo 0%) conjunctival haemorrhage 9.7% (placebo 11.8%) retinal haemorrhage 9.7% (placebo 0%) NCT03211234 · Phase 2 · registry result, not featured evidence · combination increase of subretinal hemorrhage 4.2% NCT01914159 · Phase 2 · registry result, not featured evidence 4.0 mg iSONEP conjunctival haemorrhage 53.8% intraocular pressure increased 28.2% vitreous floaters 20.5% NCT01414153 · Phase 2 · registry result, not featured evidence · combination 0.5 mg iSONEP conjunctival haemorrhage 60% activated partial thromboplastin time prolonged 12.5% vitreous floaters 12.5% NCT01414153 · Phase 2 · registry result, not featured evidence · combination conjunctival haemorrhage 34.2% retinal haemorrhage 28.9% arthralgia 7.9% NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy bruised sturnum 12.5% development of choroidal neovascularization - fellow eye 12.5% intestinal flu 12.5% NCT00896779 · Phase 2 · registry result, not featured evidence ache left eye - treatment eye 8.3% cold 8.3% corneal abrasion - both eyes 8.3% NCT00896779 · Phase 2 · registry result, not featured evidence high dose conjunctival hemorrhage 33.6% punctate keratitis 9.9% conjunctival hyperemia 8.6% NCT01089517 · Phase 2 · registry result, not featured evidence · combination low dose conjunctival hemorrhage 22.8% punctate keratitis 12.8% eye pain 6.7% NCT01089517 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTrial phases differ: Phase 4 versus Phase 3.
- dPopulation context differs: registered conditions differ.
- eTreatment context has not been resolved for both arms.
- fTrial phases differ: Phase 3 versus Phase 2.
- gAssessment timepoints differ: 52 weeks versus 24 weeks.
- hAssessment timepoints differ: 28 weeks versus 51.96 weeks.
- iTrial phases differ: Phase 2 versus Phase 3.
- jAssessment timepoints differ: 36 weeks versus 48 weeks.
- kAssessment timepoints differ: 52 weeks versus 48 weeks.
- lTrial phases differ: Phase 2 versus Phase 4.
- mAssessment timepoints differ: 16 weeks versus 104 weeks.
- nPopulation comparability has not been reviewed for 39 of these studies.
- oPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Aflibercept
show 2 more results
show 2 more results
show 2 more results
show 7 more results
show 2 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 5 more results
show 1 more result
+ 47 further endpoints in the CSV export.
Ranibizumab
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
+ 44 further endpoints in the CSV export.
Wet Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Wet Age-Related Macular Degeneration pipeline
Aflibercept · Eylea
Marketed by Regeneron Pharmaceuticals and partners
NCT00509795 · Phase 3 · completed
The trial randomly assigned 1,217 participants and used quadruple blinding with ranibizumab as an active comparator. Its hard clinical primary endpoint—maintaining vision at week 52—met the prespecified non-inferiority criterion for all three aflibercept regimens, supporting a strong evidence grade.
Next expected readout: June 2027 · NCT04932980 (registry estimate)
Reported efficacy
Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 95.1 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 95.9 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 95.1 percentage of patients (spread 0) vs Ranibizumab 0.5mg Q4 94.4 percentage of patients (spread 0) (met)
Result source: NCT00509795
Ranibizumab · Lucentis
Marketed by Roche and partners
NCT00095433 · Phase 3 · completed
The study was explicitly an extension of prior ranibizumab treatment studies (FVF1770g, FVF2128g, or FVF2425g), but it was open-label, had no comparator arm, and enrolled 100 participants. Because no results or primary endpoint findings are posted, whether the primary endpoint was met is unknown.
No aligned efficacy figure on record for this race.
Results for Wet Age-Related Macular Degeneration
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Aflibercept: 11 of 11 rows · Ranibizumab: 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Aflibercept Rows use multiple source trials | Ranibizumab Rows use multiple source trials |
|---|---|---|
| BCVA Change Letters absolute change · Letters correctly read No placebo or comparator arm | -2.1 Letters correctly read @ 104wk2 mg intravitreala,b,c,d,e NCT02581891 · Phase 4 · registry result, not featured evidence show 1 more dose-0.4 Letters correctly read @ 104wk2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence | 1 Letters correctly read @ 52wk0.5 mga,b,c,d,e NCT01780935 · Phase 3 · registry result, not featured evidence show 1 more dose0.1 Letters correctly read @ 52wk0.5 mg NCT01780935 · Phase 3 · registry result, not featured evidence |
| BCVA Change Letters absolute change · letters No placebo or comparator arm | 9 letters @ 52wka,c,d NCT02305238 · Phase 4 · registry result, not featured evidence show 1 more dose8.4 letters @ 52wk NCT02305238 · Phase 4 · registry result, not featured evidence | 12.3 letters @ 52wk0.5 mg monthlya,c,d NCT01775124 · Phase 4 · registry result, not featured evidence show 1 more dose9.6 letters @ 52wk0.5 mg PRN NCT01775124 · Phase 4 · registry result, not featured evidence |
| BCVA Gain 15 Letters absolute value · percentage points | 37.5% (n=304) vs 30.9% (n=304) Ranibizumab @ 52wk2.0mg Q4a,f,c,d,g NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 2 more doses30.6% (n=301) vs 30.9% (n=304) Ranibizumab @ 52wk2.0mg Q8 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 24.9% (n=301) vs 30.9% (n=304) Ranibizumab @ 52wk0.5mg Q4 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 | 39.1% (n=151) vs 34% (n=147) Lucentis @ 24wk1.5 mg / 0.5 mga,f,c,d,g NCT01089517 · Phase 2 · registry result, not featured evidence · combination show 1 more dose33.3% (n=147) vs 34% (n=147) Lucentis @ 24wk0.3 mg / 0.5 mg NCT01089517 · Phase 2 · registry result, not featured evidence · combination |
| CRT Change Microns absolute change · m No placebo or comparator arm | -134.4 m @ 52wka,c,d NCT02305238 · Phase 4 · registry result, not featured evidence show 1 more dose-126.1 m @ 52wk NCT02305238 · Phase 4 · registry result, not featured evidence | -147.1 m @ 52wka,c,d NCT01972789 · Phase 4 · registry result, not featured evidence show 1 more dose-125.6 m @ 52wk NCT01972789 · Phase 4 · registry result, not featured evidence |
| Lesion Area Change Mm2 absolute change · mm | -4.7 vs -3 REGN910-3 mm @ 36wk2 mg Q4 to 2 mg Q12a,h,c,d,i NCT02713204 · Phase 2 · registry result, not featured evidence show 2 more doses-3.9 vs -3 REGN910-3 mm @ 36wk2 mg Q4 to 2 mg Q8 NCT02713204 · Phase 2 · registry result, not featured evidence -5.3 vs -3 REGN910-3 mm @ 36wk2 mg Q4 to 6 mg:2 mg Q8 NCT02713204 · Phase 2 · registry result, not featured evidence | -0.6382 vs -1.1814 Lucentis mm @ 48wkh,c,d,i NCT02611778 · Phase 3 · registry result, not featured evidence |
| NEI VFQ-25 Total absolute change · score | 6.7 vs 4.9 Ranibizumab score @ 52wk2.0mg Q4a,c,d,j NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 2 more doses5.1 vs 4.9 Ranibizumab score @ 52wk2.0mg Q8 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 4.5 vs 4.9 Ranibizumab score @ 52wk0.5mg Q4 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 | 5.3 vs 3.75 Lucentis score @ 48wkc,d,j NCT02611778 · Phase 3 · registry result, not featured evidence |
| no IRF and no SRF Center Subfield event count · % of participants No placebo or comparator arm | 50.9% (n=53) @ 16wk*k,c,d,l NCT04126317 · Phase 2 · registry result, not featured evidence · converted to % from 27 Participants as posted | 37.2% (n=172) @ 104wk*a,k,c,d,l NCT01972789 · Phase 4 · registry result, not featured evidence · converted to % from 64 Participants as posted show 1 more dose32.4% (n=173) @ 104wk* NCT01972789 · Phase 4 · registry result, not featured evidence · converted to % from 56 Participants as posted |
| Dropout rate | 3.6%2.0mg Q4m NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 26 more results8.9%2.0mg Q8 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 8.9%0.5mg Q4 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 10.2%2 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 9.3%2 mg Q8 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 11.9%0.5 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 11.9%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 14%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 12.9%2 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 15.4%4 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 18.2% NCT01722045 · Phase 4 · registry result, not featured evidence 0%8 mg NCT05989126 · Phase 3 · registry result, not featured evidence 8.3%2 mg every 8 weeks NCT02540954 · Phase 3 · registry result, not featured evidence 11.3%Aflibercept Extended Dosing NCT02540954 · Phase 3 · registry result, not featured evidence —6 mg NCT03386474 · Phase 3 · registry result, not featured evidence 0.9%Brolucizumab - Overall Extension S NCT03386474 · Phase 3 · registry result, not featured evidence —Brolucizumab Overall Last 6 Months NCT03386474 · Phase 3 · registry result, not featured evidence 95% NCT00964795 · Phase 3 · registry result, not featured evidence 9.7%RBM-007 + Aflibercept NCT04200248 · Phase 2 · registry result, not featured evidence · combination 9.4%Sham + RBM-007 NCT04200248 · Phase 2 · registry result, not featured evidence · combination 3.8% NCT04126317 · Phase 2 · registry result, not featured evidence —2.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —2.0 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —4.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence 22.5% NCT01773954 · Phase na · registry result, not featured evidence | 10.7%n NCT02161575 · Phase 4 · registry result, not featured evidence show 28 more results—Intensive NCT01972789 · Phase 4 · registry result, not featured evidence 23%Intensive Retinal Fluid Regimen NCT01972789 · Phase 4 · registry result, not featured evidence —Relaxed NCT01972789 · Phase 4 · registry result, not featured evidence 17.1%Relaxed Retinal Fluid Regimen NCT01972789 · Phase 4 · registry result, not featured evidence —0.5 mg NCT01986907 · Phase 4 · registry result, not featured evidence 17.3%Ranibizumab NCT01986907 · Phase 4 · registry result, not featured evidence 6.5%0.5 mg monthly NCT01775124 · Phase 4 · registry result, not featured evidence 6%0.5 mg PRN NCT01775124 · Phase 4 · registry result, not featured evidence 5% NCT02611778 · Phase 3 · registry result, not featured evidence n/a: no completion milestone0.5 mg NCT01780935 · Phase 3 · registry result, not featured evidence n/a: no completion milestone0.5 mg NCT01780935 · Phase 3 · registry result, not featured evidence 4.4%0.5 mg as-needed (PRN) NCT00891735 · Phase 3 · registry result, not featured evidence 6.2%0.5 mg monthly NCT00891735 · Phase 3 · registry result, not featured evidence 5.5%2.0 mg as-needed (PRN) NCT00891735 · Phase 3 · registry result, not featured evidence 5.8%2.0 mg monthly NCT00891735 · Phase 3 · registry result, not featured evidence 8.3%0.5 mg monthly NCT00764738 · Phase 2/3 · registry result, not featured evidence 10.7%0.5 mg PRN NCT00764738 · Phase 2/3 · registry result, not featured evidence 20%2.0 mg monthly NCT00764738 · Phase 2/3 · registry result, not featured evidence 25%2.0 mg PRN NCT00764738 · Phase 2/3 · registry result, not featured evidence 10.7%4.0 mg NCT03211234 · Phase 2 · registry result, not featured evidence · combination 3.2%2.0 mg NCT03211234 · Phase 2 · registry result, not featured evidence · combination 3.3%1.5 mg / 0.5 mg NCT01089517 · Phase 2 · registry result, not featured evidence · combination 3.4%0.3 mg / 0.5 mg NCT01089517 · Phase 2 · registry result, not featured evidence · combination —high dose NCT01089517 · Phase 2 · registry result, not featured evidence · combination —low dose NCT01089517 · Phase 2 · registry result, not featured evidence · combination 2.3%700 µg NCT00775411 · Phase 2 · registry result, not featured evidence · combination 0% NCT01175395 · Phase 1/2 · registry result, not featured evidence · combination 16.7% NCT00517010 · Phase 1 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 1%2.0mg Q4m NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 26 more results1.3%2.0mg Q8 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 1.6%0.5mg Q4 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 1.9%2 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 2.9%2 mg Q8 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 2.6%0.5 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 3%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 4.4%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 3.2%2 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 1.6%4 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 5.2% NCT01722045 · Phase 4 · registry result, not featured evidence —8 mg NCT05989126 · Phase 3 · registry result, not featured evidence 1.2%2 mg every 8 weeks NCT02540954 · Phase 3 · registry result, not featured evidence 2.4%Aflibercept Extended Dosing NCT02540954 · Phase 3 · registry result, not featured evidence —6 mg NCT03386474 · Phase 3 · registry result, not featured evidence 0%Brolucizumab - Overall Extension S NCT03386474 · Phase 3 · registry result, not featured evidence —Brolucizumab Overall Last 6 Months NCT03386474 · Phase 3 · registry result, not featured evidence 3.7% NCT00964795 · Phase 3 · registry result, not featured evidence —RBM-007 + Aflibercept NCT04200248 · Phase 2 · registry result, not featured evidence · combination —Sham + RBM-007 NCT04200248 · Phase 2 · registry result, not featured evidence · combination 1.9% NCT04126317 · Phase 2 · registry result, not featured evidence —2.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —2.0 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —4.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence — NCT01773954 · Phase na · registry result, not featured evidence | 1.9%n NCT02161575 · Phase 4 · registry result, not featured evidence show 28 more results—Intensive NCT01972789 · Phase 4 · registry result, not featured evidence 6.3%Intensive Retinal Fluid Regimen NCT01972789 · Phase 4 · registry result, not featured evidence —Relaxed NCT01972789 · Phase 4 · registry result, not featured evidence 2.3%Relaxed Retinal Fluid Regimen NCT01972789 · Phase 4 · registry result, not featured evidence —0.5 mg NCT01986907 · Phase 4 · registry result, not featured evidence 1.2%Ranibizumab NCT01986907 · Phase 4 · registry result, not featured evidence 3%0.5 mg monthly NCT01775124 · Phase 4 · registry result, not featured evidence 3%0.5 mg PRN NCT01775124 · Phase 4 · registry result, not featured evidence 0.4% NCT02611778 · Phase 3 · registry result, not featured evidence 0.6%0.5 mg NCT01780935 · Phase 3 · registry result, not featured evidence 1.2%0.5 mg NCT01780935 · Phase 3 · registry result, not featured evidence 0.7%0.5 mg as-needed (PRN) NCT00891735 · Phase 3 · registry result, not featured evidence 0.7%0.5 mg monthly NCT00891735 · Phase 3 · registry result, not featured evidence 0%2.0 mg as-needed (PRN) NCT00891735 · Phase 3 · registry result, not featured evidence 0%2.0 mg monthly NCT00891735 · Phase 3 · registry result, not featured evidence —0.5 mg monthly NCT00764738 · Phase 2/3 · registry result, not featured evidence —0.5 mg PRN NCT00764738 · Phase 2/3 · registry result, not featured evidence —2.0 mg monthly NCT00764738 · Phase 2/3 · registry result, not featured evidence —2.0 mg PRN NCT00764738 · Phase 2/3 · registry result, not featured evidence —4.0 mg NCT03211234 · Phase 2 · registry result, not featured evidence · combination —2.0 mg NCT03211234 · Phase 2 · registry result, not featured evidence · combination —1.5 mg / 0.5 mg NCT01089517 · Phase 2 · registry result, not featured evidence · combination —0.3 mg / 0.5 mg NCT01089517 · Phase 2 · registry result, not featured evidence · combination —high dose NCT01089517 · Phase 2 · registry result, not featured evidence · combination —low dose NCT01089517 · Phase 2 · registry result, not featured evidence · combination —700 µg NCT00775411 · Phase 2 · registry result, not featured evidence · combination — NCT01175395 · Phase 1/2 · registry result, not featured evidence · combination — NCT00517010 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | 23%2.0mg Q4m NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 26 more results29.7%2.0mg Q8 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 28.9%0.5mg Q4 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 26.2%2 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 26.4%2 mg Q8 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 24.2%0.5 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 21.5%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 25.7%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 15.3%2 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 16.3%4 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 29.2% NCT01722045 · Phase 4 · registry result, not featured evidence 5.7%8 mg NCT05989126 · Phase 3 · registry result, not featured evidence 13.7%2 mg every 8 weeks NCT02540954 · Phase 3 · registry result, not featured evidence 15.6%Aflibercept Extended Dosing NCT02540954 · Phase 3 · registry result, not featured evidence 6.5%6 mg NCT03386474 · Phase 3 · registry result, not featured evidence —Brolucizumab - Overall Extension S NCT03386474 · Phase 3 · registry result, not featured evidence 6.5%Brolucizumab Overall Last 6 Months NCT03386474 · Phase 3 · registry result, not featured evidence 32.5% NCT00964795 · Phase 3 · registry result, not featured evidence 6.9%RBM-007 + Aflibercept NCT04200248 · Phase 2 · registry result, not featured evidence · combination 7.1%Sham + RBM-007 NCT04200248 · Phase 2 · registry result, not featured evidence · combination 13.2% NCT04126317 · Phase 2 · registry result, not featured evidence —2.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —2.0 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —4.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence 5% NCT01773954 · Phase na · registry result, not featured evidence | 10%n NCT02161575 · Phase 4 · registry result, not featured evidence show 28 more results33.5%Intensive NCT01972789 · Phase 4 · registry result, not featured evidence —Intensive Retinal Fluid Regimen NCT01972789 · Phase 4 · registry result, not featured evidence 33.3%Relaxed NCT01972789 · Phase 4 · registry result, not featured evidence —Relaxed Retinal Fluid Regimen NCT01972789 · Phase 4 · registry result, not featured evidence 6.7%0.5 mg NCT01986907 · Phase 4 · registry result, not featured evidence —Ranibizumab NCT01986907 · Phase 4 · registry result, not featured evidence 14.5%0.5 mg monthly NCT01775124 · Phase 4 · registry result, not featured evidence 14.5%0.5 mg PRN NCT01775124 · Phase 4 · registry result, not featured evidence 8% NCT02611778 · Phase 3 · registry result, not featured evidence 9%0.5 mg NCT01780935 · Phase 3 · registry result, not featured evidence 13.4%0.5 mg NCT01780935 · Phase 3 · registry result, not featured evidence 20.7%0.5 mg as-needed (PRN) NCT00891735 · Phase 3 · registry result, not featured evidence 24.1%0.5 mg monthly NCT00891735 · Phase 3 · registry result, not featured evidence 19.9%2.0 mg as-needed (PRN) NCT00891735 · Phase 3 · registry result, not featured evidence 19.7%2.0 mg monthly NCT00891735 · Phase 3 · registry result, not featured evidence 0%0.5 mg monthly NCT00764738 · Phase 2/3 · registry result, not featured evidence 8%0.5 mg PRN NCT00764738 · Phase 2/3 · registry result, not featured evidence 0%2.0 mg monthly NCT00764738 · Phase 2/3 · registry result, not featured evidence 0%2.0 mg PRN NCT00764738 · Phase 2/3 · registry result, not featured evidence 14.3%4.0 mg NCT03211234 · Phase 2 · registry result, not featured evidence · combination 3.2%2.0 mg NCT03211234 · Phase 2 · registry result, not featured evidence · combination —1.5 mg / 0.5 mg NCT01089517 · Phase 2 · registry result, not featured evidence · combination —0.3 mg / 0.5 mg NCT01089517 · Phase 2 · registry result, not featured evidence · combination 6.6%high dose NCT01089517 · Phase 2 · registry result, not featured evidence · combination 9.4%low dose NCT01089517 · Phase 2 · registry result, not featured evidence · combination 13.6%700 µg NCT00775411 · Phase 2 · registry result, not featured evidence · combination 10% NCT01175395 · Phase 1/2 · registry result, not featured evidence · combination 0% NCT00517010 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 2.0mg Q4m vitreous floaters 16.1% nasopharyngitis 15.1% eye disorders pain 12.8% NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 24 more results2.0mg Q8 nasopharyngitis 12.9% hypertension 10.9% eye disorders pain 10.2% NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 0.5mg Q4 nasopharyngitis 13.5% retinal haemorrhage 11.8% eye disorders pain 11.5% NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 2 mg Q4 retinal haemorrhage 27.2% visual acuity reduced 14.2% hypertension 13.3% NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 2 mg Q8 retinal haemorrhage 26.7% visual acuity reduced 19.5% macular degeneration 16.6% NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 0.5 mg Q4 retinal haemorrhage 23.6% visual acuity reduced 18.5% conjunctival haemorrhage 15.5% NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 2 mg intravitreal visual acuity reduced 15.6% conjunctival haemorrhage 14.8% nasopharyngitis 13.3% NCT02581891 · Phase 4 · registry result, not featured evidence 2 mg intravitreal conjunctival haemorrhage 13.2% nasopharyngitis 12.5% visual acuity reduced 12.5% NCT02581891 · Phase 4 · registry result, not featured evidence nasopharyngitis 21% cataract 4% conjunctival haemorrhage 3.2% NCT02305238 · Phase 4 · registry result, not featured evidence nasopharyngitis 16.3% cataract 8.1% conjunctival haemorrhage 6.5% NCT02305238 · Phase 4 · registry result, not featured evidence neovascular age-related macular degeneration 13% hypertension 8.4% conjunctival haemorrhage 7.8% NCT01722045 · Phase 4 · registry result, not featured evidence 2 mg every 8 weeks cataract 11.3% subretinal fluid 8.3% nasopharyngitis 7.1% NCT02540954 · Phase 3 · registry result, not featured evidence cataract 10.2% subretinal fluid 8.4% visual acuity reduced 8.4% NCT02540954 · Phase 3 · registry result, not featured evidence 6 mg nasopharyngitis 4.7% urinary tract infection 3.7% neovascular age-related macular degeneration - fellow eye 1.9% NCT03386474 · Phase 3 · registry result, not featured evidence urinary tract infection 5.6% nasopharyngitis 3.7% neovascular age-related macular degeneration - fellow eye 1.9% NCT03386474 · Phase 3 · registry result, not featured evidence retinal haemorrhage 12.1% retinal haemorrhage 10.5% age-related macular degeneration 9.3% NCT00964795 · Phase 3 · registry result, not featured evidence eye disorders 51.7% conjunctival haemorrhage 20.7% eye irritation 6.9% NCT04200248 · Phase 2 · registry result, not featured evidence · combination eye disorders 46.4% conjunctival haemorrhage 17.9% dry eye 14.3% NCT04200248 · Phase 2 · registry result, not featured evidence · combination neovascular age-related macular degeneration fellow eye 7.5% vitreous detachment study eye 7.5% conjunctival haemorrhage fellow eye 5.7% NCT04126317 · Phase 2 · registry result, not featured evidence 2.0 mg q12 upper respiratory tract infection 19.4% blepharitis 9.7% retinal haemorrhage 9.7% NCT00320788 · Phase 2 · registry result, not featured evidence 2.0 mg q4 urinary tract infection 19.4% eye pain 12.9% visual acuity reduced 12.9% NCT00320788 · Phase 2 · registry result, not featured evidence 0.5 mg q12 refraction disorder 12.5% headache 9.4% intraocular pressure increased 9.4% NCT00320788 · Phase 2 · registry result, not featured evidence 0.5 mg q4 hypertension 18.8% bronchitis 15.6% constipation 15.6% NCT00320788 · Phase 2 · registry result, not featured evidence 4.0 mg q12 vitreous detachment 12.9% bronchitis 9.7% eye pain 9.7% NCT00320788 · Phase 2 · registry result, not featured evidence | n nasopharyngitis 9% cough 7% lower respiratory tract infection 7% NCT02161575 · Phase 4 · registry result, not featured evidence show 20 more resultseye pain 16.2% influenza 15% influenza(non-ocular) 15% NCT01972789 · Phase 4 · registry result, not featured evidence nasopharyngitis 16.7% nasopharyngitis(non-ocular) 16.7% eye pain 13.8% NCT01972789 · Phase 4 · registry result, not featured evidence 0.5 mg neovascular age-related macular degeneration 3.6% influenza 1.6% conjunctival haemorrhage 1.4% NCT01986907 · Phase 4 · registry result, not featured evidence 0.5 mg monthly nasopharyngitis 14.5% conjunctival haemorrhage 12.7% upper respiratory tract infection 8.4% NCT01775124 · Phase 4 · registry result, not featured evidence 0.5 mg PRN nasopharyngitis 10.8% conjunctival haemorrhage 7.2% intraocular pressure increased 7.2% NCT01775124 · Phase 4 · registry result, not featured evidence neovascular age-related macular degeneration 8% conjunctival haemorrhage 5.9% nasopharyngitis 5% NCT02611778 · Phase 3 · registry result, not featured evidence 0.5 mg nasopharyngitis 7.2% conjunctival haemorrhage (study eye) 5.7% hypertension 5.4% NCT01780935 · Phase 3 · registry result, not featured evidence 0.5 mg intraocular pressure increased (study eye) 6.3% hypertension 4.5% influenza 4.5% NCT01780935 · Phase 3 · registry result, not featured evidence 0.5 mg as-needed (PRN) conjunctival haemorrhage 17.5% sinusitis 9.8% hypertension 7.6% NCT00891735 · Phase 3 · registry result, not featured evidence 0.5 mg monthly conjunctival haemorrhage 23% vitreous floaters 9.5% vitreous detachment 8% NCT00891735 · Phase 3 · registry result, not featured evidence 2.0 mg as-needed (PRN) conjunctival haemorrhage 15.1% vitreous detachment 9.9% eye pain 8.5% NCT00891735 · Phase 3 · registry result, not featured evidence 2.0 mg monthly conjunctival haemorrhage 18.6% eye pain 9.1% vitreous detachment 8.8% NCT00891735 · Phase 3 · registry result, not featured evidence 0.5 mg monthly injection site irritation 4.5% corneal abrasion 0% NCT00764738 · Phase 2/3 · registry result, not featured evidence 0.5 mg PRN corneal abrasion 4% injection site irritation 4% NCT00764738 · Phase 2/3 · registry result, not featured evidence 4.0 mg conjunctival hyperaemia 14.3% (placebo 0%) eyelid oedema 10.7% (placebo 0%) retinal haemorrhage 10.7% (placebo 0%) NCT03211234 · Phase 2 · registry result, not featured evidence · combination 2.0 mg eye pain 12.9% (placebo 0%) conjunctival haemorrhage 9.7% (placebo 11.8%) retinal haemorrhage 9.7% (placebo 0%) NCT03211234 · Phase 2 · registry result, not featured evidence · combination high dose conjunctival hemorrhage 33.6% punctate keratitis 9.9% conjunctival hyperemia 8.6% NCT01089517 · Phase 2 · registry result, not featured evidence · combination low dose conjunctival hemorrhage 22.8% punctate keratitis 12.8% eye pain 6.7% NCT01089517 · Phase 2 · registry result, not featured evidence · combination 700 µg conjunctival haemorrhage 13.6% intraocular pressure increased 6.8% NCT00775411 · Phase 2 · registry result, not featured evidence · combination ocular hypertension 70% subconjunctival hemorrhage 50% posterior vitreous detachment 20% NCT01175395 · Phase 1/2 · registry result, not featured evidence · combination |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 4 versus Phase 3.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- eAssessment timepoints differ: 104 weeks versus 52 weeks.
- fTrial phases differ: Phase 3 versus Phase 2.
- gAssessment timepoints differ: 52 weeks versus 24 weeks.
- hTrial phases differ: Phase 2 versus Phase 3.
- iAssessment timepoints differ: 36 weeks versus 48 weeks.
- jAssessment timepoints differ: 52 weeks versus 48 weeks.
- kTrial phases differ: Phase 2 versus Phase 4.
- lAssessment timepoints differ: 16 weeks versus 104 weeks.
- mPopulation comparability has not been reviewed for 21 of these studies.
- nPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Aflibercept
show 2 more results
show 2 more results
show 2 more results
show 6 more results
show 2 more results
show 3 more results
show 1 more result
show 1 more result
show 12 more results
show 3 more results
show 1 more result
+ 31 further endpoints in the CSV export.
Ranibizumab
show 11 more results
show 3 more results
show 3 more results
show 1 more result
show 1 more result
show 47 more results
show 47 more results
show 5 more results
show 1 more result
show 1 more result
show 1 more result
+ 23 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aflibercept's landscape · Ranibizumab's landscape